Decision to fund ferric derisomaltose (Monofer) in hospitals
- 6 hours ago
- 1 min read
From 1 March 2026 Pharmac is funding ferric derisomaltose (Monofer) in hospitals for people who have experienced serious reactions after other iron infusions.
In January, we consulted on a proposal to fund ferric derisomaltose (Monofer) in hospitals for people who have developed hypophosphataemia after an iron infusion.
The feedback we have received was supportive. However, clinicians told us a small number of patients who experience serious reactions to other funded iron transfusions would also benefit from this treatment.
In response to this feedback, we have decided to fund ferric derisomaltose for people who have experienced a serious reaction after other funded iron infusions. Approximately 100 people a year are expected to benefit from this treatment.
You can read the decision and summary of feedback on our website
Ngā mihi
Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
P: 0800 660 050 | www.pharmac.govt.nz
